GensKey is a health care startup founded in 2017. The company's mission revolves around empowering precision in pathogen diagnosis with advanced genetic testing technology, ensuring timely and accurate results for patients with severe infections. GensKey offers genetic testing medical diagnostics, utilizing high-throughput sequencing technology for pathogen identification. This innovative approach directly addresses challenges in detection rate, timeliness, and accuracy, ultimately ensuring timely and precise diagnoses for patients with severe infections. Notably, the company received a significant CNY100.00M Series C investment on 01 June 2021, with backing from Taikang Asset, CPE, and Oriza Seed Capital (Oriza Yuandian). This substantial investment stands as a testament to GensKey's promising potential and the confidence that prominent investors have in its groundbreaking approach to genetic testing for medical diagnostics.
No recent news or press coverage available for genskey.